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An in vitro pharmacokinetic model mimicking human serum drug concentrations, based on a dialyzer unit,
was developed to study the efficacies of continuous infusion and intermittent administration of ceftazidime over
a period of 36 h. The daily dose of ceftazidime was 300 mg/liter/24 h given either as a continuous infusion or
as three bolus doses. The intermittent dosing regimen yielded peak and trough concentrations after the fourth
dose of 92.3 (standard deviation, 8.0) and 1.4 (standard deviation, 0.9) mg/liter, respectively. Continuous
administration yielded concentrations of approximately 20 mg/liter. To study efficacy, three Pseudomonas
aeruginosa strains, ATCC 27853, CF4, and CF16, were used. The MICs of ceftazidime for these strains were 1,
4, and 16 mg/liter, respectively. Strain CF16 was killed initially during both regimens and then started to
regrow. At the end of the fourth dosing interval, i.e., after 32 h, viable counts showed no difference between the
regimens. Strains ATCC 27853 and CF4 were killed initially during both dosing schedules, and after the first
dosing interval viable counts were similar. However, after the fourth interval, there was a marked difference
between bacterial counts during continuous and intermittent infusion, being 2.2 and 2.8 loglo, respectively,
demonstrating a greater efficacy during continuous infusion. The results indicate that, in the absence of other
factors, a sustained level of ceftazidime around or slightly above the MIC is not high enough to maintain
efficacy over more than one (8-h) dosing interval. When sustained concentrations higher than four times the
MIC are employed, continuous administration in this model is more efficacious than intermittent dosing.
Time-kill curves for beta-lactam antibiotics against Pseudo-
monas aeruginosa show time-dependent killing which is maxi-
mal at relatively low concentrations (35). Concentrations much
higher than the MIC contribute no extra effect. From these
experiments, it can be deduced that continuous serum drug
concentrations above the MIC of the antibiotic used to combat
the microorganism in question should be more efficacious than
declining concentrations, as observed after intermittent dosing
(8, 10). During the latter regimen, concentrations fall below
the MIC during part of the dosing interval. It has been shown
in several animal models that continuous infusion is indeed
more efficacious than intermittent dosing (14, 21, 27). How-
ever, the half-life of most drugs is severely shortened in the
animals studied, and conclusions regarding the pharmacody-
namics in humans are difficult to make (15). For, if the
shortened half-life is taken into account, the time during which
the concentration is below the MIC applies for almost the
entire dosing interval, which is contrary to the situation as
observed in humans. This problem has, however, been partly
overcome by fractional dosing to mimic human pharmacoki-
netics (13).
In vitro simulation of human pharmacokinetics may thus
give additional information with respect to kinetics of killing of
microorganisms. Several in vitro pharmacokinetic models to
simulate human pharmacokinetics have been described, based
on either dilution (3, 4, 16, 17, 20, 23, 26, 28, 32) or diffusion (1,
5, 12, 34, 39). We developed an in vitro pharmacodynamic
model based on a dialyzer unit, which is described here. This
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model was subsequently used to study the efficacy of continu-
ous versus intermittent infusion of ceftazidime against P.
aeruginosa over a period of 36 h. Although there are some
reports suggesting a better efficacy in vitro when beta-lactam
antibiotics are dosed continuously (16), in those studies they
were given in combination with an aminoglycoside. In other
reports, the MIC is compared with the results obtained in the
pharmacodynamic model (19, 31, 37), but the circumstances
under which the MIC is determined differ from those in the
model. Furthermore, all these studies were based on dilution
models, and although correction for dilution of the bacteria
(36) can be made, artifacts due to dilution have to be pre-
cluded (18). In the present study, we used a standard dose
yielding concentrations comparable to those observed in hu-
mans during treatment. Three P. aeruginosa strains requiring
different MICs were examined.
MATERIALS AND METHODS
Model. A two-compartment model consisting of one central
compartment and several peripheral compartments was de-
signed to expose bacteria to changing antibiotic concentrations
mimicking human pharmacokinetics. Figure 1 shows a sche-
matic diagram of the model. Antibiotic was added to a central
compartment containing broth. This central compartment was
diluted from a diluent reservoir with a peristaltic pump (Econo
pump; Biorad, Veenendaal, The Netherlands). Antibiotic-
containing broth was pumped from the central compartment to
the elimination reservoir at the same pump rate, thus keeping
the central compartment at a constant volume. The peripheral
compartments consisted of disposable dialyzer units (ST23;
Baxter, Utrecht, The Netherlands) with a pore diameter of 2.8
nm. Up to four serially placed dialyzers were used to allow
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FIG. 1. Schematic diagram of the two-compartment model. Anti-
biotic is added to the central compartment by bolus injection or by use
of a pump. The volume of the central compartment is kept constant by
setting the pumps from the dilution reservoir and to the waste
reservoir at the same rate, yielding an exponential decline of the
concentration of the antibiotic. The central and the peripheral com-
partments communicate through artificial capillaries. Two peripheral
compartments are shown here; in experiments, up to four were placed
in series.
simultaneous cultures to be studied. A peristaltic pump (Bio-
rad Econo pump; 17.5 ml/min) was used to circulate the
culture in each unit. Inoculation and sampling were done
through silicone injection points (BSM-VO1 S; Hospal, Uden,
The Netherlands) with sterile needles. Each peripheral unit
contained 150 ml of bacterial culture. The contents of the
central compartment were pumped through the artificial cap-
illaries of the dialyzer unit by a peristaltic pump (Rhone
Poulenc Medical 440; 125 ml/min). A high flowrate was chosen
to obtain a fast equilibrium between the central and peripheral
compartments. The central and peripheral compartments were
placed on a shaking apparatus (125 rpm) to provide optimum
dilution of the injected antibiotic and to accelerate bacterial
growth in the peripheral compartments. Air was blown into the
broth of the central compartment through an air filter. The
complete system was placed in a room at 37°C ambient
temperature.
Media. Mueller-Hinton broth (qDifco, Amsterdam, The
Netherlands) supplemented with Ca + (22 mg/liter) and Mg2+
(12 mg/liter) was used in all experiments (MHBS).
Strains. P. aeruginosa AT1 (ATCC 27853), CF4, and CF16
were used. Strain CF4 was originally isolated from a cystic
fibrosis patient. CF16 is a laboratory mutant of strain CF4. The
MICs of ceftazidime were 1, 4, and 16 mg/liter for P. aeruginosa
ATI, CF4, and CF16, respectively. Both CF strains were
nonmucoid and showed the same growth characteristics as
strain AT1 (see below).
Antibiotic. Ceftazidime was obtained from Glaxo (Zeist,
The Netherlands). Stock solutions were prepared according to
the guidelines of the National Committee for Clinical Labora-
tory Standards (24).
MICs and growth curves. MICs were determined by both a
standard agar dilution method and a microdilution method
(24). Growth curves were made as follows. One colony from a
fresh overnight culture on Iso-Sensitest agar (Oxoid CM 471)
was suspended in MHBS and incubated overnight on a shaking
apparatus (200 rpm) at 37°C. The inoculum was obtained by
diluting this culture to approximately 5 x 105 CFU/ml and
incubating at 37°C while shaking. Samples of this log-phase
culture were taken at time (t) = 0, 1, 2, 4, 6, and 24 h and
diluted serially 10-fold in cold sterile saline on ice. A 100-pl
volume of each dilution was plated on Iso-Sensitest agar and
incubated overnight at 37°C. Growth curves were also deter-
mined in the model described above, only without injection of
antibiotic. At t = 0, each of the peripheral compartments was
filled with a log-phase culture of approximately 5 x 105
CFU/ml. Samples were taken at t = 0, 1, 2, 4, 6, and 24 h for
determination of CFU per ml as described above.
Pharmacokinetic and killing curves. The in vitro activities of
changing ceftazidime concentrations against three strains were
tested in the model described above. For the intermittent
infusion experiment, at t = 0 (immediately after the inocula-
tion of the log-phase cultures into the peripheral compart-
ments) ceftazidime solution (100 mg/liter per dose) was in-
jected in the central compartment. This was repeated after
each eighth hour, continuing for 36 h. Samples were taken at t
= 0, before and 10 and 30 min after each dose, further at every
hour until t = 10 h, then every 2 h until t = 16 h, and at t = 25,
28, 33, and 36 h. For the continuous infusion experiment, at t
= 0 an infuser (Braun, The Netherlands) was used, providing
the same daily dose of ceftazidime as during intermittent
infusion (300 mg/liter/24 h). Every 12 h, the ceftazidime
solution in the infuser was replaced. Samples were taken at t =
0, 10 min, 30 min, 1 h, and every hour until t = 10 h, then every
2 h until t = 14 h, and at t = 24, 26, 28, 30, 32, and 36 h. The
samples used for viable counts (0.5 ml) were immediately
washed (twice) with sterile saline on ice before the 10-fold
dilutions were made. The theoretical limit of detection was 4
CFU/ml. At 40 CFU/ml the coefficient of variation was <20%,
and at 100 CFU/ml it was <10%. Samples taken for ceftazi-
dime assay were stored at - 70°C. Samples were assayed for
ceftazidime by high-performance liquid chromatography as
described earlier (22). The limit of detection was 0.5 mg/liter,
and the coefficient of variation and correlation coefficient in
the range 0 to 100 mg/liter were < 10% and 0.999, respectively.
Other assays. ,-Lactamase production in the original sam-
ples was determined qualitatively at t = 0, 8, 14, 24, 32, and 36
h by a standard iodometric method (25). Briefly, a 100-pAl
sample was added to 100 plI of freshly prepared penicillin G
solution (6,000 mg/liter). Two drops of starch solution (1%)
were added, and the mixture was incubated at room temper-
ature for 30 to 60 minutes. After addition of iodine reagent,
disappearance of the then-blue color of the mixture was
considered positive.
The MICs for the isolated strains at these time points and
the pH of the medium were also determined.
Pharmacokinetic and statistical analysis. The growth rate
(pL) was determined during log phase (7). Pharmacokinetic
analysis of the time-concentration curves was done by using the
equations of Allen et al. (2). Pharmacokinetic parameters were
estimated by using the SAS NLIN computer program package
(29) with a one-compartment open model. The area under the
concentration-time curve over the first 32 h was determined by
using the log-linear trapezoidal rule (2). The t test was used to
determine statistical significance between groups. Significance
was accepted at P = 0.05 (two-tailed test).
RESULTS
Pharmacokinetic curves. Typical examples of the pharma-
cokinetic curves obtained during intermittent and continuous
infusion are shown in Fig. 2 and 3. The curves were reproduc-
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TABLE 1. Pharmacokinetic parameters during intermittent and
continuous infusion'
Mean
Trough Peak concn concn at
Dose concn (mg/liter) t1/2 (h)" end of each(m/ie)(mg/liter) interval'
(mg/liter)
1 0 96.3 ± 7.8 1.50 ± 0.23 21.1 ± 2.0
2 0.62 ± 0.16 102.3 ± 14.8 1.49 ± 0.23 19.8 ± 1.1
3 2.2 ± 1.6 84.5 ± 9.8 __d 19.7 ± 2.3
4 1.4 ± 0.9 92.3 ± 8.0 1.67 ± 0.32 19.8 ± 1.6
5 2.2 ± 0.8 86.9 ± 7.1 1.56 ± 0.17 21.2 ± 1.9
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FIG. 2. Typical example of concentration-time curves of ceftazi-
dime during intermittent bolus injection at every eighth hour (300
mg/liter/24 h). Crosses, central compartment; triangles, peripheral
compartment.
ible, and the pharmacokinetic parameters in each of the
dialyzer units were comparable (Table 1). The peak and trough
concentrations during intermittent infusion as well as the
half-lives did not differ significantly for the five doses (Table 1).
The area under the concentration-time curve from 0 to 32 h
was slightly higher during intermittent infusion (678.8 mg * h/
liter) (standard deviation [SD], 117.8) than that for continuous
infusion (609.5 mg h/liter [SD, 13.4]). The mean concentra-
tion of ceftazidime was 19.8 mg/liter (SD, 1.6) at the end of the
fourth dosing interval (Table 1).
Growth curves. The growth rates (± SD, means of four
curves) of strains AT1, CF4, and CF16 were 1.07 (SD, 0.27),
0.83 (SD, 0.28), and 1.01 (SD, 0.22) liters/h, respectively, and
not statistically significantly different from each other. The
growth rates in the model were 1.18 (SD, 0.24), 1.03 (SD, 0.18),







Killing curves. Killing curves of the P. aeruginosa strains
exposed to ceftazidime are shown in Fig. 4 and 5. During
intermittent infusion, bacteria were killed initially but started
to regrow after 7 h. After each dose, there was some killing or
suspension of growth, but then growth was resumed; this was
most apparent for strain CF16. During continuous infusion,
strains AT1 and CF4, for which the MICs were 1 and 4
mg/liter, respectively, were killed initially and then started to
regrow for a few hours, whereupon the number of CFU per
milliliter remained constant during the remainder of the
experiment. After the first dosing interval of 8 h, there was no
difference in killing by continuous and intermittent infusion for
strains AT1 and CF4. In contrast, after each subsequent dosing
interval, there was an increasing difference between the effi-
cacies of intermittent and continuous infusion in favor of the
latter, which was most marked after the last dosing interval,
i.e., after 32 h (Table 2). The difference was somewhat less for
strain AT1 than for strain CF4 because of the emergence of a
resistant mutant in one experiment whereby the MIC of
ceftazidime increased to 64 mg/liter (see below). Strain CF16
E
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FIG. 3. Typical example of concentration-time curves of ceftazi-
dime during continuous infusion (300 mg/liter/24 h). Crosses, central
compartment; triangles, peripheral compartment.
time ( hours )
FIG. 4. Killing curves for P. aeruginosa AT1 CF4, and CF16 (thin
crosses, open triangles, and open circles, respectively) and growth
controls (boldface crosses and corresponding closed symbols) during
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FIG. 5. Killing curves for P. aeruginosa AT1, CF4, and CF16 and
growth controls during continuous infusion. Data shown are geometric
means of at least two experiments. Symbols are as described for Fig. 4.
was killed initially, but during continuous infusion numbers of
bacteria were not reduced to the same extent as during
intermittent infusion. Regrowth started at approximately the
same time during both regimens, and after 32 h the numbers of
CFU per milliliter were equal (Table 2).
Emergence of resistant strains. To determine whether re-
sistant strains emerged in the course of time, the MICs for
strains isolated during the experiments were determined. The
MIC for the AT1 strain remained constant, except in one
experiment during continuous infusion. The MICs for the
strains isolated during the experiments with CF4 and CF16
increased during both continuous and intermittent infusion
and amounted to 128 mg/liter after 24 h. Thereafter no strains
requiring higher MICs could be isolated. Determination of
P-lactamase in the medium of CF16 strain revealed that a
detectable amount of P-lactamase was present at the time of
isolation of the resistant strains but not before. ,B-Lactamase
could also be detected after the emergence of the resistant
AT1 strain during continuous infusion. In contrast, ,-lacta-
mase could not be detected in the samples from the experi-
ments with strain CF4, during either continuous or intermit-
tent infusion. pH measurements of the samples showed no
deviating values.
TABLE 2. Changes in bacterial concentrations during treatment
with intermittent and continuous dosing regimens of ceftazidimea
Strain (MIC, Interval Change in bacterial concnb
mg/liter) (h) Intermittent Continuous Difference
ATCC 27853 (1) 8 3.3 3.7 0.4
32 0.7 2.9 2.2c
CF4 (4) 8 3.3 3.6 0.3
32 1.1 3.9 2.8d
CF16 (16) 8 2.8 1.3 -1.5
32 - 2.9 - 3.2 - 0.3
a Changes between 0 and 8 h (after one dosing interval) and 0 and 32 h (after
4 dosing intervals).
b Given as change in log1o CFU per milliliter between t = 0 h and t = 8 h or
t = 32 h (geometric mean of at least two experiments).
c P < 0.05 for the strains not producing P-lactamase.d p < 0.05.
DISCUSSION
Several models have been used to mimic drug concentra-
tions in plasma in humans (1, 3-5, 12, 16, 17, 20, 23, 26, 28, 32,
34, 39). The model developed here, based on diffusion, enables
the study of killing kinetics during continuous and intermittent
dosing regimens. The model proved to adequately reproduce
pharmacokinetic profiles.
In the present study, the model was used to determine
whether continuous administration of ceftazidime is more
efficacious than intermittent dosing, using dosing regimens
yielding concentrations comparable to those observed in vivo.
The half-life chosen for these experiments was approximately
1.5 h. This is in accordance with values found in vivo (11, 22,
33). The daily dose chosen yielded concentrations comparable
to those found in vivo. The killing curves of P. aeruginosa show
that, during the time course of the experiment, continuous
infusion was more efficacious than intermittent infusion for
strains AT1 and CF4. Although a bolus dose initially killed
bacteria, the P. aeruginosa strains started to regrow after
several hours. At each new dose, growth was halted for some
time or some killing was achieved, but then the bacteria
resumed growing. A similar observation was made for amoxi-
cillin (19, 31) and ampicillin (34, 37) against Escherichia coli.
After the start of continuous infusion, bacteria were killed as
well, but regrowth was substantially less or hardly present
during continuous infusion compared with that during inter-
mittent infusion. This is in agreement with the hypothesis and
some observations that gram-negative organisms exposed to
beta-lactams resume growth when concentrations fall below a
certain level (9) and that high concentrations do not exert an
additional effect as, for instance, for the quinolones (6).
The most consistent index of bactericidal activity found by
White et al. (37), when studying efficacy of ampicillin against E.
coli, was the area under the concentration-time curve and not
the time above the MIC (TMIC). The TMIc did not covary
strongly with the MIC, and the authors suggest that the high
frequency of emergence of resistant strains may have masked
the importance of the TMIC. Since during continuous infusion
the TMIC was incessant for strains AT1 and CF4 at the start of
the experiments, and continuous infusion was more efficacious
than intermittent infusion, we conclude that the TMIC is an
important parameter. The suggestion of White et al. (37) that
their failure to find the TMIC to be an important parameter
may have been caused by the high frequency of emergence of
resistant strains may therefore be correct. Studying the efficacy
of beta-lactams in patients with pneumonia, Schentag et al.
(30) also found the TMIC to be important.
It has been argued that the emergence of resistance, or the
continued isolation of strains, is possibly an artifact of in vitro
systems due to the adherence of bacteria to the walls of the
incubation flasks (18). This observation was made in dilution
models, and control experiments in this type of model can rule
this out (18, 37). In the diffusion model used in the present
study, the importance of adherence of bacteria is not easily
assessable. However, if adherence were a main determinant of
the outcome of the studies, one might expect that there would
have been no difference in the outcome of the dosage regi-
mens.
To determine whether the MIC itself may influence the
interaction between bacteria and antibiotic, we examined three
strains. P. aeruginosa CF4 and CF16 were 4- and 16-fold less
susceptible to ceftazidime, respectively, than strain AT1, and
the growth rates were comparable with each other. Although
the concentration during continuous infusion was maintained
at approximately 20 mg of ceftazidime per liter, which is higher
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than the MIC for strain CF16, this particular strain started to
regrow after some time. This was due to the appearance of
strains requiring MICs up to 128 mg/liter, a phenomenon that
was also observed during intermittent infusion. Regrowth due
to resistant subpopulations has also been observed in other
studies with a comparable model. However, in those studies
the bacteria were exposed to enoxacin and gentamicin, which
belong to another group of antibiotics (6, 38). 3-Lactamase,
not detectable in the earlier samples, was present in the
medium from approximately the same time onwards, possibly
facilitating regrowth. These results also indicate that the
apparent resistance was probably due to the production of
13-lactamase by P. aeruginosa. This was probably due to the
emergence of a derepressed mutant, as was determined by
exposure after cefoxitin (results not shown). The regrowth
during continuous administration, despite continuous concen-
trations above the MIC, implies that these concentrations are
not high enough to prevent regrowth.
In contrast to this observation for strain CF16 was the
appearance of resistant strains of CF4 requiring a high MIC
during both continuous and intermittent infusion. These
strains were highly resistant, as determined by the MIC, yet
appreciable growth did not occur. The absence of growth of
the isolated mutants of CF4 is not easy to explain. It could be
that if the experiment had lasted longer regrowth would have
been observed, although this did not occur during the 12 h that
the strain was present. The presence of r-lactamase could not
be detected, suggesting that resistance was cell wall mediated
in these cases.
The results of these experiments suggest that when the
antibiotic is the only agent present to exert efficacy, as is the
case in neutropenic patients, a sustained level around or
slightly above the MIC is not high enough. The strains exposed
to a sustained concentration of five times the MIC or more
were inhibited in their growth, indicating that a concentration
four to five times the MIC is effective. When sustained
concentrations higher than five times the MIC are employed,
continuous administration in this model is more efficacious
than intermittent dosing.
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